Aurobindo Pharma Share Plunged 7.52%, Stock Enters in Top Losers on NIFTYMIDCAP150

Aurobindo pharma share price falls 7.52% to ₹1,111.40 per share, placing the stock among the top losers on the NIFTYMIDCAP150 at 15:07:00 PM. The fall came amid volatility in the midcap and profit bookings in Pharma and PSU stocks. 

At around 15:07:00 PM, stocks like KPR Mill, Bharti Hexacom, and NHPC also witnessed fall in prices which reflects cautious sentiment across the index. 

Reasons Behind Aurobindo Pharma Share Price Fall

Despite no immediate negative earnings announcement, Aurobindo Pharma share price plunged around 7.52% today. Here are the key reasons driving severe fall in the share price:

• Market weakness in NIFTYMIDCAP150
• Short-term profit bookings by investors post recent gains. 
• Investors caution due to regulatory and operational updates in the pharma sector. 

The stock movement comes even as the company continues to report steady improvement in revenue and profitability.

Key financial ratios of Aurobindo Pharma Share

• ROE (FY25): 10.67
• Debt-to-equity: 0.24
• Book value per share: ₹562.21

Despite moderate ROE as compared to past years, the balance sheet of Aurobindo Pharma continues to stay comfortable with manageable leverage. 

Aurobindo Pharma Share Financial Performance 

Resilient and gradual recovery of Aurobindo Pharma financials caught investors attention. Here are the financials for year ended March 2025. 

• Net profit: ₹3,515.26 crore against ₹3,186.13 crore in FY24. 
• Consolidated revenue: ₹31,723.73 crore against ₹29,001.87 crore in FY24.

It embarks a healthy YOY growth in top and bottom line of Aurobindo Pharma which strengthened the company’s long-term outlook. 

Quarterly results highlight consistent growth

The latest quarterly data also reflects operational stability:

• Revenue increased from ₹7,978.52 crore in Dec 2024 to ₹8,645.90 crore in Dec 2025
• Net profit rose from ₹843.98 crore to ₹909.43 crore in the same period
• EPS improved to 15.67 in the December 2025 quarter

These numbers indicate sustained demand across key markets, including the US and emerging geographies.

Corporate updates and regulatory developments

Recently, the company:

• Released an investor presentation outlining growth strategy and operational focus
• Announced the board meeting outcome on February 9, 2026
• Completed a US FDA inspection at Unit III of Eugia Pharma Specialities Ltd., its wholly-owned subsidiary

Regulatory clarity around inspections is often closely tracked by investors, especially for pharma exporters.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice.